



## Cyclooxygenase (COX) and Lipoxygenase (LOX) in the Inflammogenesis of Cancer

Guest Editor:

**Prof. Dr. Randall E. Harris**

Colleges of Public Health &  
Medicine, The Ohio State  
University, Columbus, OH, USA

Deadline for manuscript  
submissions:  
**closed (15 March 2023)**

### Message from the Guest Editor

Dear Colleagues,

We are pleased to invite you to contribute your research article to a special issue entitled “Cyclooxygenase (COX) and Lipoxygenase (LOX) in the Inflammogenesis of Cancer”.

The aim of the special issue is to update and underscore scientific evidence from molecular, animal, and human investigations suggesting that constitutive overexpression of either COX or LOX drives carcinogenesis, and reciprocally, that COX/LOX blockade has strong potential for cancer prevention and therapy.

We welcome contributions that address the impact of COX/LOX overexpression on essential molecular features of carcinogenesis (mutagenesis, mitogenesis, angiogenesis, reduced apoptosis, immunosuppression and metastasis); as well as epidemiologic and clinical investigations of anti-inflammatory agents and their potential role in the chemoprevention and therapy of cancer.

Prof. Dr. Randall E. Harris  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

Cancers Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)